enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System
Rhea-AI Summary
enVVeno Medical (NASDAQ:NVNO) reported full-year 2025 results and strategic progress on its next‑generation enVVe System. Pre-clinical development is complete and the company is in active FDA discussions to initiate a pivotal trial in 2026. Cash and investments were $28.2M at year-end, with an expected 2026 burn of $4–5M per quarter, providing runway into mid‑2027 if key clinical milestones are met. 2025 net loss narrowed to $19.5M from $21.8M in 2024; R&D expense was $10.0M (down 19%), and SG&A was $10.9M.
Positive
- Pre-clinical complete for enVVe System
- Pivotal trial planned for 2026 with active FDA discussions
- Cash $28.2M at December 31, 2025; runway into mid‑2027
Negative
- Net loss $19.5M in 2025
- R&D spend down 19% YoY to $10.0M
- Higher 2026 burn forecast: $4–5M per quarter
News Market Reaction – NVNO
In the Mar 27 session, NVNO gained 0.76%, reflecting a mild positive market reaction. Argus tracked a peak move of +8.6% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 31 | Q3 2025 earnings | Positive | +1.1% | Q3 2025 results with cash runway to Q2 2027 and enVVe progress. |
| Aug 01 | Q2 2025 earnings | Neutral | +5.6% | Q2 2025 results, cash of $35.1M and mixed burn/loss metrics. |
| Aug 01 | Q2 2024 earnings | Positive | -0.9% | Q2 2024 results with lower burn, strong cash and positive trial data. |
| May 08 | Q1 2024 earnings | Positive | -2.5% | Q1 2024 results, solid cash and positive efficacy data for VenoValve. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings updates have produced mixed reactions, with positive/neutral fundamentals sometimes met by negative price moves, indicating inconsistent alignment between results and market response.
Over the past two years, NVNO’s earnings releases have focused on cash runway and development of venous valve programs. Prior updates highlighted cash balances between $31.0M and $42.9M, quarterly cash burn in the $3.5–4.2M range, and ongoing progress of VenoValve and enVVe. Price reactions have been inconsistent, with both gains (e.g., +5.64% on Aug 1, 2025) and declines (e.g., -2.55% on May 8, 2024), underscoring variable sentiment around similar financial updates.
Key Terms
chronic venous insufficiency medical
chronic venous disease medical
transcatheter-based medical
pivotal trial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Company accelerated development of the enVVe® System, completing pre-clinical studies and progressing toward a 2026 pivotal trial initiation
Strong financial position expected to provide an operating runway into mid-2027 through the achievement of key clinical milestones
IRVINE, CA / ACCESS Newswire / March 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced financial results for the year ended December 31, 2025 and provided a corporate update highlighting its strategic focus on the development of its next-generation enVVe® System.
Robert Berman, Chief Executive Officer of enVVeno Medical Corporation, stated, "2025 represented a significant inflection point for the Company. Following the FDA's decision regarding the VenoValve®, we made the strategic determination to accelerate development of the enVVe System, a less invasive, transcatheter-based approach designed to address prior regulatory considerations while broadening the potential physician adoption base." Mr. Berman added, "With pre-clinical development complete and active discussions underway with the FDA, we are now focused on initiating our pivotal trial in 2026 and believe the enVVe System represents a transformative opportunity to address a large and underserved patient population suffering from severe chronic venous insufficiency."
Chronic venous disease is the most prevalent chronic condition in the United States, affecting an estimated
The enVVe System is a first-in-class, non-surgical, transcatheter-based replacement venous valve designed to treat severe deep CVI by restoring proper one-way blood flow in the leg veins. The system is intended to eliminate the need for open surgery, reduce procedural risk, expand adoption across multiple physician specialties and improve patient quality of life. Looking ahead, the Company's primary focus in 2026 will be advancing the enVVe System into clinical development, including finalizing alignment with the FDA on the pivotal trial design, initiating the pivotal trial and progressing toward potential regulatory approval.
Summary of Financial Results for the Full Year 2025
For the year ended December 31, 2025, the Company reported a net loss of
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775
SOURCE: enVVeno Medical Corporation
View the original press release on ACCESS Newswire